跳至主要内容
临床试验/NCT04542876
NCT04542876已完成不适用

Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study

Aarogyam UK1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2020年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
46
试验地点
1
主要终点
Virologic clearance

研究概览

简要总结

The emergence of asymptomatic patients poses a significant challenge to the prevention and treatment of the epidemic.There have not been any treatment options that reduce the viral load or preventive options that reduce the risk of developing severe conditions.Therefore, present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in asymptomatic patients with COVID-19

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All hospitalised cases above 18 years of age,
  • Diagnosed with Covid-19
  • Asymptomatic at the time of admission
  • Agree to give consent

排除标准

  • Symptoms relating to Covid-19
  • Severe vomiting
  • Respiratory failure or requiring mechanical ventilation
  • Patients having alanine transaminase (ALT) or aspartate transaminase (AST) > 5 times the upper range of normal limits
  • Patients with Covid-19 in critical condition or ARDS or NIAD 8 -point ordinal score-2
  • Patients with uncontrolled diabetes mellitus
  • Malignant,
  • Chronic renal failure or
  • On immunosuppressive medication

研究组 & 干预措施

Ayurveda

Experimental

Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.

干预措施: Guduchi Ghan Vati (Drug)

结局指标

主要结局

Virologic clearance

时间窗: 14 days

Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result

次要结局

  • Clinically relevant adverse effects(14 days)
  • Hospital Stay(14 days)
  • Laboratory tests(change from baseline to 14 days)

研究者

发起方
Aarogyam UK
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验